(Q36582624)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

review article

1 reference

title

Cardiovascular safety profiles of aromatase inhibitors : a comparative review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Jean-Marc Nabholtz

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

page(s)

785-801

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16944964%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.2165/00002018-200629090-00003

29 December 2019

exact match

0 references

cites work

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

12 December 2020

Cancer and venous thromboembolism

1 reference

12 December 2020

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

12 December 2020

Venous thromboembolism and cancer: a two-way clinical association

1 reference

12 December 2020

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

12 December 2020

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

12 December 2020

Deaths: leading causes for 2002.

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

12 December 2020

Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

1 reference

12 December 2020

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

12 December 2020

The inhibition of coronary atherosclerosis by estrogens in cholesterol-fed chicks

1 reference

12 December 2020

Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

The preclinical pharmacology of "Arimidex" (anastrozole; ZD1033)--a potent, selective aromatase inhibitor

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

12 December 2020

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

12 December 2020

Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial

1 reference

12 December 2020

Aromatase and breast cancer

1 reference

12 December 2020

The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L).

1 reference

12 December 2020

Ageing and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety upda

1 reference

12 December 2020

Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.

1 reference

12 December 2020

Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)

1 reference

12 December 2020

Thrombophilic state in breast cancer

1 reference

12 December 2020

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

12 December 2020

Haemostatic variables and menopausal status: influence of hormone replacement therapy

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

Plasma changes in breast cancer patients during endocrine therapy--lipid measurements and nuclear magnetic resonance (NMR) spectroscopy

1 reference

12 December 2020

Prevention of thrombotic disorders in cancer patients undergoing chemotherapy

1 reference

12 December 2020

An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole

1 reference

12 December 2020

Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

1 reference

12 December 2020

Update on cardiovascular disease in post-menopausal women

1 reference

12 December 2020

Can menopause be considered an independent risk factor for cardiovascular disease?

1 reference

12 December 2020

The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane o

1 reference

12 December 2020

Effects of estrogen replacement on the progression of coronary-artery atherosclerosis

1 reference

12 December 2020

Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).

1 reference

12 December 2020

Morning cortisol production in coronary heart disease patients

1 reference

12 December 2020

Increased risk of atherosclerosis in women after the menopause

1 reference

12 December 2020

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer

1 reference

12 December 2020